Paige Company

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
Technology: Preclinical R&D
Industry: Data processing
Headquarters: New York, New York, United States
Founded Date: 2018-02-01
Employees Number: 101-250
Funding Status: Late Stage Venture
Investors Number: 7
Total Funding: 220000000
Estimated Revenue: $1M to $10M
Last Funding Date: 2021-01-14
Last Funding Type: Series C

Visit Website
info@paige.ai
https://www.twitter.com/paige_ai?lang=en
Register and Claim Ownership